Lag Times between Lymphoproliferative Disorder and Clinical Diagnosis of Chronic Lymphocytic Leukemia: A Prospective Analysis Using Plasma Soluble CD23 | Citedby Results | Cancer Epidemiology, Biomarkers & Prevention | American Association for Cancer Research

Skip to Main Content

Skip Nav Destination

Lag Times between Lymphoproliferative Disorder and Clinical Diagnosis of Chronic Lymphocytic Leukemia: A Prospective Analysis Using Plasma Soluble CD23

Cancer Epidemiol Biomarkers Prev (2015) 24 (3): 538–545.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Identifying proteomic risk factors for cancer using prospective and exome analyses of 1463 circulating proteins and risk of 19 cancers in the UK Biobank

Keren Papier
Joshua R. Atkins
Tammy Y. N. Tong
Kezia Gaitskell
Trishna Desai
Chibuzor F. Ogamba
Mahboubeh Parsaeian
Gillian K. Reeves
Ian G. Mills
Tim J. Key
Karl Smith-Byrne
Ruth C. Travis

Nature Communications (2024) 15 (1)

Clinical significance of serum sCD23 and B-cell maturation antigen levels in patients with chronic lymphocytic leukemia

TalibMohammed Ameen
HaithemAhmed Al-Rubaie

Iraqi Journal of Hematology (2022) 11 (2): 134.

Serum levels of hsa‐miR‐16‐5p, hsa‐miR‐29a‐3p, hsa‐miR‐150‐5p, hsa‐miR‐155‐5p and hsa‐miR‐223‐3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

International Journal of Cancer (2020) 147 (5): 1315.

Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study

Fatemeh Saberi Hosnijeh
Lina van der Straten
Arnon P. Kater
Marinus H.J. van Oers
Ward F.M. Posthuma
Martine E.D. Chamuleau
Mar Bellido
Jeanette K. Doorduijn
Michel van Gelder
Mels Hoogendoorn
Fransien de Boer
G. Doreen te Raa
J. Martijn Kerst
Erik W.A. Marijt
Reinier A.P. Raymakers
Harry R. Koene
Martijn R. Schaafsma
Johan A. Dobber
Sanne H. Tonino
Sabina S. Kersting
Anton W. Langerak
Mark-David Levin

Experimental Hematology (2020) 89: 55.

Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development

Fatemeh Saberi Hosnijeh
Pieter M. Kolijn
Delphine Casabonne
Alexandra Nieters
Marta Solans
Sabine Naudin
Pietro Ferrari
James D. Mckay
Elisabete Weiderpass
Vittorio Perduca
Caroline Besson
Francesca Romana Mancini
Giovanna Masala
Vittorio Krogh
Fulvio Ricceri
José M. Huerta
Dafina Petrova
Núria Sala
Antonia Trichopoulou
Anna Karakatsani
Carlo La Vecchia
Rudolf Kaaks
Federico Canzian
Dagfinn Aune
Heiner Boeing
Matthias B. Schulze
Aurora Perez-Cornago
Anton W. Langerak
Vincent H. J. van der Velden
Roel Vermeulen

Scientific Reports (2020) 10 (1)

AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer—a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI)

D. Ferastraoaru
H. J. Bax
C. Bergmann
M. Capron
M. Castells
D. Dombrowicz
E. Fiebiger
H. J. Gould
K. Hartmann
U. Jappe
G. Jordakieva
D. H. Josephs
F. Levi-Schaffer
V. Mahler
A. Poli
D. Rosenstreich
F. Roth-Walter
M. Shamji
E. H. Steveling-Klein
M. C. Turner
E. Untersmayr
S. N. Karagiannis
E. Jensen-Jarolim

Clinical and Translational Allergy (2020) 10 (1)

Elevated soluble CD23 level indicates increased risk of B cell non-Hodgkin’s lymphomas: evidence from a meta-analysis

Yi-shu Huang
Xiang Zhou
Zhi-fang Yang
Zheng-tao Lv

Annals of Hematology (2018) 97 (8): 1317.

Potential reverse causation?

Sok‐Ja Janket
Leland K. Ackerson
Jukka H. Meurman

International Journal of Cancer (2017) 140 (9): 2168.